A phase I study using a [68Ga]-labeled anti-HER2 sdAb has been concluded for PET/CT assessment of HER2 expression in breast carcinoma, and a phase II trial is currently ongoing with the same tracer for characterization of HER2 expression in brain metastases of breast cancer patients [14,15]. Here, ERBB2 is linked to breast cancer.